Post-discharge is a vulnerable phase for heart failure patients.

Slides:



Advertisements
Similar presentations
Topic 1 What is patient safety?. Learning objective Understand the discipline of patient safety and its role in minimizing the incidence and impact of.
Advertisements

Transitions of Care: From Hospital to SNF Steven Tam, MD Assistant Clinical Professor UCI Program in Geriatrics, Internal Medicine.
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Considering the Impact of Social Determinants on Readmissions June 26, 2014 Intermountain HEN Andrew Masica, MD, MSCI Chief Clinical Effectiveness Officer.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
A Brief Introduction to Epidemiology - VII (Epidemiologic Research Designs: Demographic, Mortality & Morbidity Studies) Betty C. Jung, RN, MPH, CHES.
Krumholz, Harlan; MD, SM; Lin, Zhenqiu; Keenan, Patricia; PhD, MHS; Chen, Jersey; MD, MPH; Ross, Joseph; MD, MHS; Drye, Elizabeth; MD, SM; Bernheim, Susannah;
“Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)” Daniel E. Forman, MD; Christopher.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
חזק בהגנה לבבית Valsartan in Heart Failure
“ Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients with Ischemic Stroke ” Gregg C. Fonarow,
analysis from the SHIFT study
Raghu Upender, MD Assistant Professor in Neurology Medical Director Vanderbilt Sleep Disorders Center.
Stroke - the size of the problem. What is a stroke? What is a transient ischaemic attack? What is the size of the problem?
Quality of Care and Outcomes in Patients with Diabetes Hospitalized with Ischemic Stroke Findings From Get With The Guidelines-Stroke Reeves MJ; Vaidya.
Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.
Fonarow GC, et al. J Am Coll Cardiol. 2007;50:768  777. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized.
RHP 14 Learning Collaborative July 18, DSRIP Project Overview  Key project areas at Odessa Regional Medical Center Speech Pathology Diabetes Education.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
HRET/K-HEN Readmissions Race Office Hour Building a Multidisciplinary Care Transitions Team January 25, 2013.
Reduction Of Hospital Readmissions Hany Salama, MD Diplomat ABIM IM Hospice and Palliative Care Sleep Medicine.
Learn more about ways to Bend the Curve in health care costs at: Made possible through support from: Preventing Hospital Readmissions:
Achieving High-Quality, Low Cost Care Amidst Payment System Reform
Coverage with Evidence Development Implantable Cardioverter Defibrillators 1 Sean Tunis MD, MSc June 23, 2009.
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
The burden Of heart failure
Do Heart Failure Disease Management Programs Make Financial Sense Under a Bundled Payment System? Zubin J. Eapen, Shelby D. Reed, Lesley H. Curtis, Adrian.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:
New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
From Knowledge to Practice Translation A Multidisciplinary Intervention to Reduce 30 day Heart Failure Readmissions.
Incorporating Telemedicine (TM) to Reduce the Rates of Rehospitalizations in the Chronic Heart Failure (CHF) Population Roshini M. Mathew RN, BSN, Erica.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
Heart failure and comorbidities
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
III. Measures of Morbidity: Morbid means disease. Morbidity is an important part of community health. It gives an idea about disease status in that community.
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.
Management Strategies for Post-Intervention in Patients with CAD VBWG.
Severe Hypoglycemia Identifies Vulnerable Patients With Type 2 Diabetes at Risk for Premature Death and All-Site Cancer: The Hong Kong Diabetes Registry.
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
Clinical need for determination of vulnerable plaques
Courtney selby, Pharm.d. arcare pgy1 Community pharmacy resident
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Modest Increase in Peak VO2 Is Related to Better Clinical Outcomes in Chronic Heart Failure PatientsClinical Perspective by Ann M. Swank, John Horton,
Circ Cardiovasc Qual Outcomes
Circ Cardiovasc Qual Outcomes
Recently Diagnosed vs Chronic HF Associated with Better Outcomes
Acute Heart Failure.
Heart Failure and Hospital Readmissions
Heart Failure Management Coordinated Care Approaches
اتجاهات أنماط المرض بين السكان. المراحل الأربع للتحول الوبائى.
Antimicrobial Therapy for Life-threatening Infections: Speed is Life
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
New Strategies to Reduce HF Readmissions
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.
Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87
Clinical Practice Guidelines: What, Why, Who?
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
Presentation transcript:

Post-discharge is a vulnerable phase for heart failure patients

“Hospitalized heart failure is associated with unacceptable high post-discharge mortality and rehospitalization rate” 1 REFERENCES Gheorghiade M, Shah AN, Vaduganathan M, et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Failure Clin. 2013;9: Joynt KE, Jha AK. Who has higher readmission rates for heart failure, and why? Implications for efforts to improve care using financial incentives. Circ Cardiovasc Qual Outcomes. 2011;4: Chun S, Tu JV, Wijeysundera HC, Austin PC, Wang X, Levy D, Lee DS. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail. May 2, doi / CIRCHEARTFAILURE Accessed April 19, Krumholz HM. Post-hospital syndrome – an acquired, transient condition of generalized risk. N Engl J Med. 2013;368; Marti CN, Fonarow GC, Gheorghiade M, Butler J. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail. 2013;6:  Several recent publications 1-5 discuss important issues on hospitalized heart failure patients who have unacceptably high post-discharge mortality and rehospitalization rates. A high event rate despite all available therapies makes this topic a health care priority in terms of patient well-being and expenditure.  With the aging of the population and an ever-increasing burden of disease, the cumulative incidence and prevalence of heart failure requiring hospitalization have evolved into epidemic proportions. The costs associated with hospitalized heart failure have added demands from society, government, and payers to improve outcomes.

Mortality is particularly high in the early phase after hospitalization Marti NC, Fonarow GC, Gheorghiade M, Bulter J. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail 2013;6: All-cause mortality after discharge for HF is high at the 1 st month 1 Changes in risk profile after hospitalization. Hasard ratio of all-cause mortality after discharge from hospital for first hospitalization for heart failure

Rehospitalization is particularly high in the early phase after hospitalization Gheorghiade M, Shah AN, Vaduganathan M, et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Failure Clin. 2013;9: Marti NC, Fonarow GC, Gheorghiade M, Butler J. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail. 2013;6: Joynt KE, Jha AK. Who has higher readmission rates for heart failure, and why? Implications for efforts to improve care using financial incentives. Circ Cardiovasc Qual Outcomes. 2011;4: Chun S, Tu JV, Wijeysundera HC, Austin PC, Wang X, Levy D, Lee DS. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail. May 2, doi / CIRCHEARTFAILURE Accessed April 19, days from discharge 1 1 patient out of 4 is readmitted patient out of 2 is readmitted months from discharge

Weeks to months post-discharge at high risk may be viewed as a “vulnerable phase” 1, Krumholz HM. Post-hospital syndrome – an acquired, transient condition of generalized risk. N Engl J Med. 2013;368; Marti NC, Fonarow GC, Gheorghiade M, Butler J. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail. 2013;6:  The post-discharge period is described as an “acquired, transient condition of generalized risk” or “a period of vulnerability”. 1  Comprehensive strategies should focus on factors during hospitalization and also during the early recovery period soon after discharge to target stressors that probably contribute to the vulnerability of patients. 1,2

Initiating therapy during hospitalization is suggested to reduce the risk of adverse outcomes 1-2  At discharge, patients can be considered to be in a stable chronic heart failure state at high risk for adverse outcomes   “Initiating therapies in patients who are stabilized in the hospital and continued long-term provides a potent option to improve long-term clinical outcomes.” 1   “Delaying initiation of potentially effective therapies for weeks to months post discharge risks unabated high risk for adverse events in the meantime.” Gheorghiade M, Shah AN, Vaduganathan M, et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Failure Clin. 2013;9: Marti NC, Fonarow GC, Gheorghiade M, Butler J. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail. 2013;6: